David C. Sperry

638 total citations
25 papers, 476 citations indexed

About

David C. Sperry is a scholar working on Pharmaceutical Science, Analytical Chemistry and Materials Chemistry. According to data from OpenAlex, David C. Sperry has authored 25 papers receiving a total of 476 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Pharmaceutical Science, 8 papers in Analytical Chemistry and 6 papers in Materials Chemistry. Recurrent topics in David C. Sperry's work include Drug Solubulity and Delivery Systems (15 papers), Analytical Methods in Pharmaceuticals (8 papers) and Crystallization and Solubility Studies (5 papers). David C. Sperry is often cited by papers focused on Drug Solubulity and Delivery Systems (15 papers), Analytical Methods in Pharmaceuticals (8 papers) and Crystallization and Solubility Studies (5 papers). David C. Sperry collaborates with scholars based in United States, United Kingdom and Greece. David C. Sperry's co-authors include Michael Hawley, James M. Farrar, Christopher S. Polster, Jun Qian, Anthony J. Midey, Evelyn D. Lobo, Ivelina Gueorguieva, Patrick J. Marsac, Xiaoqiao He and M. Barone and has published in prestigious journals such as The Journal of Chemical Physics, Pain and Chemical Physics Letters.

In The Last Decade

David C. Sperry

24 papers receiving 462 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David C. Sperry United States 13 271 168 105 104 64 25 476
Jan Westergren Sweden 12 383 1.4× 339 2.0× 132 1.3× 88 0.8× 70 1.1× 20 797
M. Duval France 14 115 0.4× 145 0.9× 39 0.4× 17 0.2× 89 1.4× 19 601
Dwayne T. Friesen United States 12 585 2.2× 303 1.8× 177 1.7× 70 0.7× 87 1.4× 23 951
Michael D. Likar United States 12 146 0.5× 51 0.3× 256 2.4× 234 2.3× 42 0.7× 17 616
Chong‐Hui Gu United States 7 240 0.9× 507 3.0× 222 2.1× 9 0.1× 55 0.9× 8 757
Vishal Koradia Denmark 11 320 1.2× 345 2.1× 163 1.6× 15 0.1× 101 1.6× 15 652
Noriyuki Takata Japan 12 372 1.4× 548 3.3× 139 1.3× 17 0.2× 51 0.8× 25 989
Fernando Alvarez‐Núñez United States 13 333 1.2× 438 2.6× 164 1.6× 13 0.1× 58 0.9× 26 812
Daniel P. McNamara United States 10 358 1.3× 660 3.9× 152 1.4× 6 0.1× 50 0.8× 10 916
Michael Hawley United States 9 255 0.9× 218 1.3× 67 0.6× 4 0.0× 61 1.0× 15 391

Countries citing papers authored by David C. Sperry

Since Specialization
Citations

This map shows the geographic impact of David C. Sperry's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David C. Sperry with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David C. Sperry more than expected).

Fields of papers citing papers by David C. Sperry

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David C. Sperry. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David C. Sperry. The network helps show where David C. Sperry may publish in the future.

Co-authorship network of co-authors of David C. Sperry

This figure shows the co-authorship network connecting the top 25 collaborators of David C. Sperry. A scholar is included among the top collaborators of David C. Sperry based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David C. Sperry. David C. Sperry is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Broad, Lisa M., Jeffrey G. Suico, P. Kellie Turner, et al.. (2025). Preclinical and clinical evaluation of a novel TRPA1 antagonist LY3526318. Pain. 166(8). 1893–1908. 3 indexed citations
2.
Liu, Ye, et al.. (2025). Development of a Quantitative Method for Formulation Microenvironmental pH Assessment. Molecular Pharmaceutics. 22(9). 5493–5503.
4.
Salehi, Niloufar, Gislaine Kuminek, Jozef Al-Gousous, et al.. (2021). Improving Dissolution Behavior and Oral Absorption of Drugs with pH-Dependent Solubility Using pH Modifiers: A Physiologically Realistic Mass Transport Analysis. Molecular Pharmaceutics. 18(9). 3326–3341. 22 indexed citations
5.
Martinez, Marilyn N., Sara Carlert, Murat Cirit, et al.. (2019). Workshop Report: USP Workshop on Exploring the Science of Drug Absorption. Dissolution Technologies. 26(3). 38–66. 1 indexed citations
6.
Friedel, Horst Dieter, Cynthia K. Brown, Lucinda F. Buhse, et al.. (2018). FIP Guidelines for Dissolution Testing of Solid Oral Products. Journal of Pharmaceutical Sciences. 107(12). 2995–3002. 19 indexed citations
7.
Tsume, Yasuhiro, Sanjaykumar R. Patel, Nikoletta Fotaki, et al.. (2018). In Vivo Predictive Dissolution and Simulation Workshop Report: Facilitating the Development of Oral Drug Formulation and the Prediction of Oral Bioperformance. The AAPS Journal. 20(6). 100–100. 8 indexed citations
8.
Aburub, Aktham, David C. Sperry, Shobha Bhattachar, et al.. (2018). Relative Bioavailability Risk Assessment: A Systematic Approach to Assessing In Vivo Risk Associated With CM&C-Related Changes. Journal of Pharmaceutical Sciences. 108(1). 8–17. 7 indexed citations
9.
Pack, Brian W., et al.. (2017). Development of an in vivo -relevant drug product performance method for an amorphous solid dispersion. Journal of Pharmaceutical and Biomedical Analysis. 142. 307–314. 7 indexed citations
10.
Ding, Xuan, Jeffrey S. Day, & David C. Sperry. (2016). Physiologically Based Absorption Modeling to Design Extended-Release Clinical Products for an Ester Prodrug. The AAPS Journal. 18(6). 1424–1438. 2 indexed citations
11.
Hetrick, Evan M., et al.. (2014). Characterization of a Novel Cross-Linked Lipase: Impact of Cross-Linking on Solubility and Release from Drug Product. Molecular Pharmaceutics. 11(4). 1189–1200. 15 indexed citations
12.
Lobo, Evelyn D., et al.. (2012). Optimization of LY545694 Tosylate Controlled Release Tablets Through Pharmacoscintigraphy. Pharmaceutical Research. 29(10). 2912–2925. 8 indexed citations
13.
Sperry, David C., et al.. (2010). Relative Bioavailability of Three Different Solid Forms of PNU-141659 as Determined with the Artificial Stomach-Duodenum Model. Journal of Pharmaceutical Sciences. 99(9). 3923–3930. 43 indexed citations
14.
Sperry, David C., et al.. (2010). In Vitro Monitoring of Dissolution of an Immediate Release Tablet by Focused Beam Reflectance Measurement. Molecular Pharmaceutics. 7(5). 1508–1515. 15 indexed citations
15.
He, Xiaoqiao, M. Barone, Patrick J. Marsac, & David C. Sperry. (2007). Development of a rapidly dispersing tablet of a poorly wettable compound—formulation DOE and mechanistic study of effect of formulation excipients on wetting of celecoxib. International Journal of Pharmaceutics. 353(1-2). 176–186. 21 indexed citations
16.
Sperry, David C., et al.. (2005). Relative bioavailability estimation of carbamazepine crystal forms using an artificial stomach-duodenum model. Journal of Pharmaceutical Sciences. 95(1). 116–125. 103 indexed citations
17.
Sperry, David C., et al.. (2004). Spectroscopy and reactivity of size-selected Mg+-ammonia clusters. The Journal of Chemical Physics. 121(17). 8375–8384. 19 indexed citations
18.
Sperry, David C., et al.. (2001). Spectroscopy and reactivity of size-selected Mg+–methanol clusters. The Journal of Chemical Physics. 114(14). 6180–6189. 32 indexed citations
19.
Sperry, David C., et al.. (1999). Spectroscopic studies of mass selected clusters of Sr+ solvated by H2O and D2O. The Journal of Chemical Physics. 111(18). 8469–8480. 48 indexed citations
20.
Sperry, David C., et al.. (1999). Cluster size specific chemistry: deuterium atom pickup in Sr+ solvated by ammonia. Chemical Physics Letters. 304(5-6). 350–356. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026